In fact, only SA costs were higher for NAT compared with the other groups; DP costs were lower than GA, indicating that even if PwMS receiving NAT as first-line treatment, are having higher MS disability at baseline, and probably higher disease activity compared with those receiving IFN or GA,21 still, their ability to maintain their long-term work capacity is higher. This evidence concerns the gene BRD2 and myeloid sarcoma.